Patient and donor characteristics and transplantation procedures
. | Recipients with ligand present, no. (%) . | Recipients with ligand absent, no. (%) . |
|---|---|---|
| ALL | 18 (27.3) | 27 (24.1) |
| CR1 | 2 (3.0) | 7 (6.3) |
| CR2 | 11 (16.7) | 9 (8.0) |
| Relapse | 2 (3.0) | 6 (5.4) |
| Refractory | 3 (4.5) | 5 (4.5) |
| Primary AML | 13 (19.7) | 34 (30.4) |
| CR1 | 6 (9.1) | 25 (22.3) |
| CR2 | 0 (0) | 2 (1.8) |
| Refractory | 2 (3.0) | 4 (3.6) |
| Relapse | 5 (7.6) | 3 (2.7) |
| Secondary AML | 6 (9.1) | 4 (3.6) |
| CR1 | 3 (4.5) | 2 (1.8) |
| Refractory | 1 (1.5) | 0 (0) |
| Relapse | 2 (3.0) | 1 (0.9) |
| N/A | 0 (0) | 1 (0.9) |
| CML | 20 (30.3) | 41 (36.6) |
| Chronic phase 1 | 13 (19.7) | 17 (15.2) |
| Chronic phase 2 | 0 (0) | 1 (0.9) |
| Accelerated phase | 5 (7.6) | 20 (17.9) |
| Blast crisis | 2 (3.0) | 3 (2.7) |
| MDS | 9 (13.6) | 6 (5.4) |
| RA | 2 (3.0) | 3 (2.7) |
| RAEB | 4 (6.1) | 1 (0.9) |
| RAEB-t | 3 (4.5) | 1 (0.9) |
| CMML | 0 (0) | 1 (0.9) |
| Patient/donor sex | ||
| M/M | 25 (37.9) | 40 (35.7) |
| M/F | 14 (21.2) | 24 (21.4) |
| F/M | 12 (18.2) | 27 (24.1) |
| F/F | 15 (22.7) | 21 (18.8) |
| Patient/donor ethnicity | ||
| White | 59 (89.4) | 103 (92.0) |
| Nonwhite | 7 (10.6) | 9 (8.0) |
| Patient/donor CMV status* | ||
| Positive/positive | 10 (15.2) | 24 (21.4) |
| Positive/negative | 12 (18.2) | 25 (22.3) |
| Negative/positive | 10 (15.2) | 12 (10.7) |
| Negative/negative | 34 (51.5) | 51 (45.5) |
| Acute GVHD† | 10 (15.2) | 24 (21.4) |
| mAb/complement TCD method | ||
| T10/B9 | 48 (72.7) | 96 (85.7) |
| OKT3 | 18 (27.3) | 16 (14.3) |
. | Recipients with ligand present, no. (%) . | Recipients with ligand absent, no. (%) . |
|---|---|---|
| ALL | 18 (27.3) | 27 (24.1) |
| CR1 | 2 (3.0) | 7 (6.3) |
| CR2 | 11 (16.7) | 9 (8.0) |
| Relapse | 2 (3.0) | 6 (5.4) |
| Refractory | 3 (4.5) | 5 (4.5) |
| Primary AML | 13 (19.7) | 34 (30.4) |
| CR1 | 6 (9.1) | 25 (22.3) |
| CR2 | 0 (0) | 2 (1.8) |
| Refractory | 2 (3.0) | 4 (3.6) |
| Relapse | 5 (7.6) | 3 (2.7) |
| Secondary AML | 6 (9.1) | 4 (3.6) |
| CR1 | 3 (4.5) | 2 (1.8) |
| Refractory | 1 (1.5) | 0 (0) |
| Relapse | 2 (3.0) | 1 (0.9) |
| N/A | 0 (0) | 1 (0.9) |
| CML | 20 (30.3) | 41 (36.6) |
| Chronic phase 1 | 13 (19.7) | 17 (15.2) |
| Chronic phase 2 | 0 (0) | 1 (0.9) |
| Accelerated phase | 5 (7.6) | 20 (17.9) |
| Blast crisis | 2 (3.0) | 3 (2.7) |
| MDS | 9 (13.6) | 6 (5.4) |
| RA | 2 (3.0) | 3 (2.7) |
| RAEB | 4 (6.1) | 1 (0.9) |
| RAEB-t | 3 (4.5) | 1 (0.9) |
| CMML | 0 (0) | 1 (0.9) |
| Patient/donor sex | ||
| M/M | 25 (37.9) | 40 (35.7) |
| M/F | 14 (21.2) | 24 (21.4) |
| F/M | 12 (18.2) | 27 (24.1) |
| F/F | 15 (22.7) | 21 (18.8) |
| Patient/donor ethnicity | ||
| White | 59 (89.4) | 103 (92.0) |
| Nonwhite | 7 (10.6) | 9 (8.0) |
| Patient/donor CMV status* | ||
| Positive/positive | 10 (15.2) | 24 (21.4) |
| Positive/negative | 12 (18.2) | 25 (22.3) |
| Negative/positive | 10 (15.2) | 12 (10.7) |
| Negative/negative | 34 (51.5) | 51 (45.5) |
| Acute GVHD† | 10 (15.2) | 24 (21.4) |
| mAb/complement TCD method | ||
| T10/B9 | 48 (72.7) | 96 (85.7) |
| OKT3 | 18 (27.3) | 16 (14.3) |
There were 66 recipients with ligand present and 112 recipients with ligand absent. Median total nucleated cell count/kg was 6.96 × 107 for recipients with ligand present, and 7.35 × 107 for recipients with ligand absent; median patient age was 34.9 and 33.5 years for recipients with ligand present and absent, respectively.
RA indicates refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; M, male; F, female; mAb, monoclonal antibody.
CMV status was tested by serologic methods.
GVHD grade ≥ 2.